505 related articles for article (PubMed ID: 27193083)
1. Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.
Lau DH; Hogseth M; Phillips EC; O'Neill MJ; Pooler AM; Noble W; Hanger DP
Acta Neuropathol Commun; 2016 May; 4(1):49. PubMed ID: 27193083
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.
Usardi A; Pooler AM; Seereeram A; Reynolds CH; Derkinderen P; Anderton B; Hanger DP; Noble W; Williamson R
FEBS J; 2011 Aug; 278(16):2927-37. PubMed ID: 21692989
[TBL] [Abstract][Full Text] [Related]
3. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease.
Liu W; Zhao J; Lu G
Biochem Biophys Res Commun; 2016 Sep; 478(2):852-7. PubMed ID: 27520374
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
Derkinderen P; Scales TM; Hanger DP; Leung KY; Byers HL; Ward MA; Lenz C; Price C; Bird IN; Perera T; Kellie S; Williamson R; Noble W; Van Etten RA; Leroy K; Brion JP; Reynolds CH; Anderton BH
J Neurosci; 2005 Jul; 25(28):6584-93. PubMed ID: 16014719
[TBL] [Abstract][Full Text] [Related]
5. Disease-related modifications in tau affect the interaction between Fyn and Tau.
Bhaskar K; Yen SH; Lee G
J Biol Chem; 2005 Oct; 280(42):35119-25. PubMed ID: 16115884
[TBL] [Abstract][Full Text] [Related]
6. AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.
Cochran JN; Diggs PV; Nebane NM; Rasmussen L; White EL; Bostwick R; Maddry JA; Suto MJ; Roberson ED
J Biomol Screen; 2014 Dec; 19(10):1338-49. PubMed ID: 25156556
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of tau by fyn: implications for Alzheimer's disease.
Lee G; Thangavel R; Sharma VM; Litersky JM; Bhaskar K; Fang SM; Do LH; Andreadis A; Van Hoesen G; Ksiezak-Reding H
J Neurosci; 2004 Mar; 24(9):2304-12. PubMed ID: 14999081
[TBL] [Abstract][Full Text] [Related]
8. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines.
Xia D; Li C; Götz J
Biochim Biophys Acta; 2015 May; 1852(5):913-24. PubMed ID: 25558816
[TBL] [Abstract][Full Text] [Related]
9. A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity.
Rush T; Roth JR; Thompson SJ; Aldaher AR; Cochran JN; Roberson ED
Neurobiol Dis; 2020 Feb; 134():104668. PubMed ID: 31698056
[TBL] [Abstract][Full Text] [Related]
10. Fyn, a potential target for Alzheimer's disease.
Yang K; Belrose J; Trepanier CH; Lei G; Jackson MF; MacDonald JF
J Alzheimers Dis; 2011; 27(2):243-52. PubMed ID: 21799250
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.
An WL; Cowburn RF; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ
Am J Pathol; 2003 Aug; 163(2):591-607. PubMed ID: 12875979
[TBL] [Abstract][Full Text] [Related]
12. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role.
Ho GJ; Hashimoto M; Adame A; Izu M; Alford MF; Thal LJ; Hansen LA; Masliah E
Neurobiol Aging; 2005 May; 26(5):625-35. PubMed ID: 15708437
[TBL] [Abstract][Full Text] [Related]
13. Tau-S214 Phosphorylation Inhibits Fyn Kinase Interaction and Increases the Decay Time of NMDAR-mediated Current.
Jos S; Poulose R; Kambaru A; Gogoi H; Dalavaikodihalli Nanjaiah N; Padmanabhan B; Mehta B; Padavattan S
J Mol Biol; 2024 Feb; 436(4):168445. PubMed ID: 38218365
[TBL] [Abstract][Full Text] [Related]
14. Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease.
Zahratka JA; Shao Y; Shaw M; Todd K; Formica SV; Khrestian M; Montine T; Leverenz JB; Bekris LM
Neurobiol Aging; 2017 Mar; 51():43-53. PubMed ID: 28033507
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
16. The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.
Sontag JM; Nunbhakdi-Craig V; White CL; Halpain S; Sontag E
J Biol Chem; 2012 Apr; 287(18):14984-93. PubMed ID: 22403409
[TBL] [Abstract][Full Text] [Related]
17. Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.
Li C; Götz J
EMBO J; 2017 Nov; 36(21):3120-3138. PubMed ID: 28864542
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture.
Miyamoto T; Stein L; Thomas R; Djukic B; Taneja P; Knox J; Vossel K; Mucke L
Mol Neurodegener; 2017 May; 12(1):41. PubMed ID: 28526038
[TBL] [Abstract][Full Text] [Related]
19. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.
Roberson ED; Halabisky B; Yoo JW; Yao J; Chin J; Yan F; Wu T; Hamto P; Devidze N; Yu GQ; Palop JJ; Noebels JL; Mucke L
J Neurosci; 2011 Jan; 31(2):700-11. PubMed ID: 21228179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
